Role of miRNA-145, 148, and 185 and Stem Cells in Prostate Cancer

Abstract

MicroRNAs (miRNAs) are small non-coding RNA molecules that play a role in cancer linked to the regulation of important cellular processes and pathways involving tumorigenesis, cell proliferation, differentiation, and apoptosis. A lot of human miRNA sequences have been identified which are linked to cancer pathogenesis. MicroRNAs, in prostate cancer (PC), play a relevant role as biomarkers, show a specific profile, and have been used as therapeutic targets. Prostate cancer (PC) is the most frequently diagnosed cancer in men. Clinical diagnoses among the gold standards for PC diagnosis and monitoring are prostate-specific antigen (PSA) testing, digital rectal examination, and prostate needle biopsies. PSA screening still has a large grey area of patients, which leads to overdiagnosis. Therefore, new biomarkers are needed to improve existing diagnostic tools. The miRNA expression profiles from tumour versus normal tissues are helpful and exhibit significant differences not only between cancerous and non-cancerous tissues, but also between different cancer types and subtypes. In this review, we focus on the role of miRNAs-145, 148, and 185 and their correlation with stem cells in prostate cancer pathogenesis. MiR-145, by modulating multiple oncogenes, regulates different cellular processes in PC, which are involved in the transition from localised to metastatic disease. MiR-148 is downregulated in high-grade tumours, suggesting that the miR-148-3 family might act as tumour suppressors in PC as a potential biomarker for detecting this disease. MiR-185 regulation is still unclear in being able to regulate tumour processes in PC. Nevertheless, other authors confirm the role of this miRNA as a tumour suppressor, suggesting its potential use as a suitable biomarker in disease prognosis. These three miRNAs are all involved in the regulation of prostate cancer stem cell behaviour (PCSCs). Within this contest, PCSCs are often involved in the onset of chemo-resistance in PC, therefore strategies for targeting this subset of cells are strongly required to control the disease. Hence, the relationship between these two players is interesting and important in prostate cancer pathogenesis and in PCSC stemness regulation, in the attempt to pave the way for novel therapeutic targets in prostate cancer.

Humanin and Its Pathophysiological Roles in Aging: A Systematic Review

“…A hallmark of aging appears to be the presence of large numbers of dysfunctional mitochondria, which may be the source of inflammatory stimuli and contribute to immune impairment. Some authors speculate that mitochondrial dysfunction may be beneficial to the cell because it may elicit an effective stress response [ 72 ]. Through these, mitochondria regulate not only energy production but a cellular homeostasis that includes a range of processes such as immune/inflammatory responses, proteostasis, adaptive responses to stress, and apoptosis [ 96 , 97 , 98 ].…”

“…It would be crucial to have control over autophagy regulation in order to develop a cure for several diseases. For this reason, there has been increasing attention on the therapeutic modulation of autophagy, due to its cytoprotective nature [ 72 , 109 , 110 , 111 ]. If external retrograde control through the administration of humanin, autophagy, were possible, it would be an excellent therapeutic tool as it could be stimulated to increase normal cellular function and thus counteract senescence, as well as inhibited to treat cancer [ 72 , 112 , 113 ].…”

MicroRNAs as clinical tools for diagnosis, prognosis, and therapy in prostate cancer

“…[ 115 ] demonstrated the role of miR-34a in modulating PCSCs and metastasis by directly repressing CD44 expression. Furthermore, a recent review discussed extensively the involvement of other miRNAs, including miR-145, miR-148, and miR-185, in regulating the behavior of PCSCs and contributing to PCa invasiveness and metastasis [ 116 ].…”

Role of Nano-miRNAs in Diagnostics and Therapeutics

“…MiR-141 is a promising biomarker for human prostate cancer [ 13 , 14 , 15 ]. This miRNA has been identified with high selectivity in human serum with a LOD of ca.…”